NR1D2 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Hemoglobin, for comparison, has a Hill coefficient of usually 2.8–3.0. In these cases of cooperative binding hemocyanin was arranged in protein sub-complexes of 6 subunits (hexamer) each with one oxygen binding site; binding of oxygen on one unit in the complex would increase the affinity of the neighboring units. Each hexamer complex was arranged together to form a larger complex of dozens of hexamers. In one study, cooperative binding was found to be dependent on hexamers being arranged together in the larger complex, suggesting cooperative binding between hexamers. Hemocyanin oxygen-binding profile is also affected by dissolved salt ion levels and pH. Hemocyanin is made of many individual subunit proteins, each of which contains two copper atoms and can bind one oxygen molecule (O2). Each subunit weighs about 75 kilodaltons (kDa). Subunits may be arranged in dimers or hexamers depending on species; the dimer or hexamer complex is likewise arranged in chains or clusters with weights exceeding 1500 kDa. The subunits are usually homogeneous, or heterogeneous with two variant subunit types. Because of the large size of hemocyanin, it is usually found free-floating in the blood, unlike hemoglobin.
The rationale for establishing emission standards for non-road engines is that they are a significant source of pollution. The engines of on-road vehicles have advanced emission controls which are not found on those non-road engines. The non-road engines also emit air pollution particles at much higher rates. The emission standards are based on the engine classifications and vary in various jurisdictions. The main model regulations that are used by many countries are the United States Environmental Protection Agency through the section 213 of the Clean Air Act (42 U.S.C. 7547) and the directive of the European Commission (the "mother" Directive 97/68/EC, the amendments Directive 2002/88/EC, Directive 2004/26/EC, Directive 2006/105/EC, Directive 2011/88/EU and the last amendment Directive 2012/46/EU). The directives cover diesel engines, spark-ignition engines, constant-speed engines, railcars, locomotives and inland waterway vessels. In Europe, the term "non-road mobile machinery" (NRMM) is used to clarify that the definition refers to non-road engines that are capable of self-propulsion. In the European Union, in 2023, the Commission and the Council proposed to harmonize road safety requirements to ease non-road mobile machinery (such as lawn mowers, harvesters or bulldozers) to circulate on public roads and replace local European union member states regulations. This would only apply to machine with maximum speed greater than 6 km/hour (around 4 miles per hour). Next legislative step would be in the European parliament.
=== Measurement === PTH can be measured in the blood in several different forms: intact PTH; N-terminal PTH; mid-molecule PTH, and C-terminal PTH, and different tests are used in different clinical situations. The level may be stated in pg/dL or pmol/L (sometimes abbreviated mmol/L); multiply by 0.1060 to convert from pg/dL to pmol/L. A US source states the average PTH level to be 8–51 pg/mL. In the UK the biological reference range is considered to be 1.6–6.9 pmol/L. Normal total plasma calcium level ranges from 8.5 to 10.2 mg/dL (2.12 mmol/L to 2.55 mmol/L). The PTH assay may be liable to interference in rare cases.
Sources: en.wikipedia.org
=== Formulated intermediate moisture foods === Many types of food are specially formulated to achieve water activity in the IMF range. Food ingredients are mixed with salt and/or sugar, and additives (such as propylene glycol and potassium sorbate) and then subjected to processing methods such as cooking, extrusion or dehydration to result in an intermediate moisture final product. Examples of formulated IMF are confectioneries and pet food.
== Mechanism of action == Two main ideas about how it might work have been proposed over the years. The first idea, which has been proven wrong, is that insulin makes cells more permeable, so that the chemotherapy drugs are absorbed faster into cells. The other idea is that insulin might cause the cells to start dividing, which makes them more susceptible to destruction of many cytotoxic chemotherapy drugs.
Iced tea can be purchased, like soda, in canned or bottled form at vending machines and convenience stores; usually, this pre-made tea is sweetened with corn syrup, and sometimes some other flavoring, such as lemon or raspberry, is added. Also, like other soft drinks, it can be purchased as a fountain drink, though in some establishments it is pumped from a bag-in-box, and in others, it is simply poured from a separate container that contains freshly brewed tea. In restaurants, iced tea is usually served unsweetened except in the Southeastern United States where iced tea is much more common and is available both sweet and unsweetened and "iced tea" is often considered to be "sweet tea" unless otherwise specified. The reason for the pre-sweetening is that it may be difficult to dissolve sugar in iced tea, even with constant stirring. The result can be insufficiently sweetened tea or gritty, undissolved sugar crystals in the tea. In the Northern United States and the Western United States, "tea" generally means the hot beverage and iced tea is referred to by name. Iced tea's popularity in the United States has led to an addition to standard cutlery sets; the iced tea spoon is a standard flatware teaspoon, but with a long handle, suitable for stirring sugar into the taller glasses commonly used for iced tea.
Sources: en.wikipedia.org
Echtes Eisenkraut (German: "true ironherb") IJzerhard (Dutch: "iron-hard") Læge-Jernurt (Danish: "medical ironherb") Železník lekársky (Slovak: "medical ironherb") Rohtorautayrtti (Finnish: "medical ironherb") Közönséges vasfű (Hungarian: "common irongrass") Common vervain was scientifically described by Carl Linnaeus his 1753 Species Plantarum. The scientific name references the Ancient Roman term verbena, used for any sacrificial herb considered very powerful (as described e.g. by Pliny the Elder). Officinalis, meanwhile, is Latin for "used in medicine or herbalism".
The disease was first described by the Neapolitan physician Giovanni Semmola in 1834 and Gaetano Conte in 1836. However, Duchenne muscular dystrophy is named after the French neurologist Guillaume-Benjamin-Amand Duchenne (1806–1875), who in the 1861 edition of his book Paraplégie hypertrophique de l'enfance de cause cérébrale, described and detailed the case of a boy who had this condition. A year later, he presented photos of his patient in his Album de photographies pathologiques. In 1868, he gave an account of 13 other affected children. Duchenne was the first to do a biopsy to obtain tissue from a living patient for microscopic examination.
In rail transport, the Single European Railway Directive 2012 requires that ownership of tracks and operating companies are separated to prevent conflicts of interest and pricing, particularly to ensure that trains can run from one member state to another. Most European railways are publicly owned, and each train enterprise must have separate accounts and member states should run railways 'at the lowest possible cost for the quality of service required'. The Rail Passenger Rights Regulation 2007 article 17 states that 25% of a ticket price should be refunded if there is a one-hour delay, and 50% over two hours, with a threshold of €4 to claim. Passengers have a right to take bicycles on trains where they are not overcrowded, there must be clear information on tickets, and there are rights to make reservations. Finally, in air transport, under the Flight Compensation Regulation (EC) No 261/2004 there is a minimum right of €250 compensation for 2 hour delay on 1500 km flight, €400 compensation for 3 hour delay or more on a 1500–3500 km flight, and €600 for 4 hours in flights over 3500 km flight, plus the right to refreshments, hotels, and alternative transport. There are not yet duties on airline companies to invest in research for clean fuels, and eliminate unnecessary flight paths when clean land transport alternatives (such as high-speed rail) exist. Finally, the 'right to housing assistance' is a basic part of EU law. House prices are affected by monetary policy (above), but otherwise the EU's involvement is so far limited to minimal environmental standards.
== Treatment == The injury can be debilitating for athletes of many sports who need to accelerate, quickly change direction, or jump. Use of the toes is not possible during the healing process. Since the toes are necessary for proper push-off when accelerating, those sorts of athletic activities should be almost completely curtailed. An extended healing period of one or more months is often required. Because of the anatomy of the distal foot and the unique use of the foot, it is often impossible to properly tape or brace the joint. Although difficult, it is not impossible to tape the toe to limit extension (upward bend of toe). Additionally, wearing a shoe with a rigid sole (often a metal plate) and cushioned innersole will help minimize extension of the joint. Anti-inflammatory medication, as well as physical therapy, is recommended. Turf toe is usually healed in about 2–3 weeks. It can become more serious if left untreated, and may cause serious problems for the athlete. Treating the injury includes icing of the area, elevating the foot, or possibly the use of custom orthotics.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.